We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
Malaria kills more than half a million and affects over 225 million people every year.
Following a number of groundbreaking clinical trials, Professor Sir Nick White and his colleagues successfully demonstrated the effectiveness of artemisinin in the treatment of malaria. They also pioneered artemisinin-combination therapy (ACT), the most effective and fast-acting malaria treatment in the world.
A new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS) launched on 15 September 2023. This is the third Phase I clinical trial of the ChAdOx1 MERS vaccine, developed by researchers at the Pandemic Sciences Institute. It is the first trial in older people.
